Immune response profile elicited by the model antigen ovalbumin expressed in fusion with the bacterial OprI lipoprotein

Molecular Immunology

Volumn 64, Issue 1, 2015, Pages 36-45

  Basto, Afonso P ^a   Badenes, Marina ^a,b   Almeida, Sílvia C P ^c   Martins, Carlos ^a   Duarte, António ^a,b   Santos, Dulce M ^a,d   Leitão, Alexandre ^a,d  

^a FACULDADE DE MEDICINA VETERINÁRIA   (Portugal)

^b INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

^c INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^d INSTITUTO DE INVESTIGAÇÃO CIENTÍFICA TROPICAL   (Portugal)

Author keywords

Adjuvant; Immunomodulation; Melanoma mouse model; Outer membrane lipoprotein I; TLR2; Vaccine

Indexed keywords

BACTERIAL PROTEIN; CANCER VACCINE; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2B ANTIBODY; IMMUNOGLOBULIN G2C ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 27; INTERLEUKIN 6; OPRI LIPOPROTEIN; OPRI LIPOPROTEIN OVALBUMIN FUSION PROTEIN; OVALBUMIN; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIBODY; ANTIGEN; CYTOKINE; HYBRID PROTEIN; LIPOPROTEIN; OUTER MEMBRANE LIPOPROTEIN I, BACTERIA;

ANIMAL CELL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN PRESENTATION; ARTICLE; BONE MARROW DERIVED DENDRITIC CELL; CD4+ T LYMPHOCYTE; CROSS PRESENTATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOMODULATION; MELANOMA; MOUSE; NONHUMAN; SPLEEN CELL; ANIMAL; BONE MARROW CELL; C57BL MOUSE; CROSS REACTION; CYTOLOGY; DENDRITIC CELL; EXPERIMENTAL MELANOMA; IMMUNITY; IMMUNIZATION; IMMUNOLOGY; MALE; PATHOLOGY; SECRETION (PROCESS); SPLEEN;

BACTERIA (MICROORGANISMS); MURINAE; MUS;

ANIMALS; ANTIBODIES; ANTIGEN PRESENTATION; ANTIGENS; BACTERIAL PROTEINS; BONE MARROW CELLS; CD4-POSITIVE T-LYMPHOCYTES; CROSS REACTIONS; CYTOKINES; DENDRITIC CELLS; IMMUNITY; IMMUNIZATION; LIPOPROTEINS; MALE; MELANOMA, EXPERIMENTAL; MICE, INBRED C57BL; OVALBUMIN; RECOMBINANT FUSION PROTEINS; SPLEEN;

EID: 84920081327     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2014.10.020     Document Type: Article

References (61)

1. Agrawal S., Agrawal A., Doughty B., Gerwitz A., Blenis J., Van Dyke T., Pulendran B. Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J. Immunol. 2003, 171:4984-4989.
2. Akdis C.A., Kussebi F., Pulendran B., Akdis M., Lauener R.P., Schmidt-Weber C.B., Klunker S., Isitmangil G., Hansjee N., Wynn T.A., Dillon S., Erb P., Baschang G., Blaser K., Alkan S.S. Inhibition of T helper 2-type responses, IgE production and eosinophilia by synthetic lipopeptides. Eur. J. Immunol. 2003, 33:2717-2726.
3. Aliahmadi E., Gramlich R., Grützkau A., Hitzler M., Krüger M., Baumgrass R., Schreiner M., Wittig B., Wanner R., Peiser M. TLR2-activated human langerhans cells promote Th17 polarization via IL-1beta, TGF-beta and IL-23. Eur. J. Immunol. 2009, 39:1221-1230.
4. Andrieu M., Loing E., Desoutter J.F., Connan F., Choppin J., Gras-Masse H., Hanau D., Dautry-Varsat A., Guillet J.G., Hosmalin A. Endocytosis of an HIV-derived lipopeptide into human dendritic cells followed by class I-restricted CD8(+) T lymphocyte activation. Eur. J. Immunol. 2000, 30:3256-3265.
5. Baier W., Masihi N., Huber M., Hoffmann P., Bessler W.G. Lipopeptides as immunoadjuvants and immunostimulants in mucosal immunization. Immunobiology 2000, 201:391-405.
6. Basto A.P., Leitão A. Targeting TLR2 for vaccine development. J. Immunol. Res. 2014, 2014:22.
7. Basto A.P., Morais J., Marcelino E., Leitão A., Santos D.M. An efficient depyrogenation method for recombinant bacterial outer membrane lipoproteins. Protein Expression Purif. 2014, 98:10-17.
8. Basto A.P., Piedade J., Ramalho R., Alves S., Soares H., Cornelis P., Martins C., Leitão A. A new cloning system based on the OprI lipoprotein for the production of recombinant bacterial cell wall-derived immunogenic formulations. J. Biotechnol. 2012, 157:50-63.
9. Baz A., Buttigieg K., Zeng W., Rizkalla M., Jackson D.C., Groves P., Kelso A. Branched and linear lipopeptide vaccines have different effects on primary CD4+ and CD8+ T-cell activation but induce similar tumor-protective memory CD8+ T-cell responses. Vaccine 2008, 26:2570-2579.
10. Blander J.M. Phagocytosis and antigen presentation: a partnership initiated by Toll-like receptors. Ann. Rheum. Dis. 2008, 67(Suppl 3):iii44-iii49.
11. Brightbill H.D., Libraty D.H., Krutzik S.R., Yang R.B., Belisle J.T., Bleharski J.R., Maitland M., Norgard M.V., Plevy S.E., Smale S.T., Brennan P.J., Bloom B.R., Godowski P.J., Modlin R.L. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science (New York, NY) 1999, 285:732-736.
12. Chua B.Y., Eriksson E.M., Brown L.E., Zeng W., Gowans E.J., Torresi J., Jackson D.C. A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection. Vaccine 2008, 26:4866-4875.
13. Coffman R.L., Sher A., Seder R.A. Vaccine adjuvants: putting innate immunity to work. Immunity 2010, 33:492-503.
14. Cote-Sierra J., Bredan A., Toldos C.M., Stijlemans B., Brys L., Cornelis P., Segovia M., de Baetselier P., Revets H. Bacterial lipoprotein-based vaccines induce tumor necrosis factor-dependent type 1 protective immunity against Leishmania major. Infect. Immun. 2002, 70:240-248.
15. Dillon S., Agrawal A., Van Dyke T., Landreth G., McCauley L., Koh A., Maliszewski C., Akira S., Pulendran B. A Toll-like receptor 2 ligand stimulates Th2 responses in vivo, via induction of extracellular signal-regulated kinase mitogen-activated protein kinase and c-Fos in dendritic cells. J. Immunol. 2004, 172:4733-4743.
16. Dillon S., Agrawal S., Banerjee K., Letterio J., Denning T.L., Oswald-Richter K., Kasprowicz D.J., Kellar K., Pare J., van Dyke T., Ziegler S., Unutmaz D., Pulendran B. Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigen-presenting cells and immunological tolerance. J. Clin. Invest. 2006, 116:916-928.
17. Durand V., Wong S.Y., Tough D.F., Le Bon A. Shaping of adaptive immune responses to soluble proteins by TLR agonists: a role for IFN-alpha/beta. Immunol. Cell Biol. 2004, 82:596-602.
18. Ghielmetti M., Zwicker M., Ghielmetti T., Simon M.M., Villiger P.M., Padovan E. Synthetic bacterial lipopeptide analogs facilitate naive CD4+ T cell differentiation and enhance antigen-specific HLA-II-restricted responses. Eur. J. Immunol. 2005, 35:2434-2442.
19. Goodridge H.S., Reyes C.N., Becker C.A., Katsumoto T.R., Ma J., Wolf A.J., Bose N., Chan A.S.H., Magee A.S., Danielson M.E., Weiss A., Vasilakos J.P., Underhill D.M. Activation of the innate immune receptor Dectin-1 upon formation of a 'phagocytic synapse'. Nature 2011, 472:471-475.
20. Huang C.Y., Chen J.J., Shen K.Y., Chang L.S., Yeh Y.C., Chen I.H., Chong P., Liu S.J., Leng C.H. Recombinant lipidated HPV E7 induces a Th-1-biased immune response and protective immunity against cervical cancer in a mouse model. PLoS One 2012, 7:e40970.
21. Huber M., Baier W., Bessler W.G., Heinevetter L. Modulation of the Th1/Th2 bias by lipopeptide and saponin adjuvants in orally immunized mice. Immunobiology 2002, 205:61-73.
22. Imanishi T., Hara H., Suzuki S., Suzuki N., Akira S., Saito T. Cutting edge: TLR2 directly triggers Th1 effector functions. J. Immunol. 2007, 178:6715-6719.
23. Ishii K.J., Akira S. Toll or toll-free adjuvant path toward the optimal vaccine development. J. Clin. Immunol. 2007, 27:363-371.
24. Jackson D.C., Lau Y.F., Le T., Suhrbier A., Deliyannis G., Cheers C., Smith C., Zeng W., Brown L.E. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:15440-15445.
25. Karumuthil-Melethil S., Perez N., Li R., Vasu C. Induction of innate immune response through TLR2 and dectin 1 prevents type 1 diabetes. J. Immunol. 2008, 181:8323-8334.
26. Kasturi S.P., Skountzou I., Albrecht R.A., Koutsonanos D., Hua T., Nakaya H.I., Ravindran R., Stewart S., Alam M., Kwissa M., Villinger F., Murthy N., Steel J., Jacob J., Hogan R.J., Garcia-Sastre A., Compans R., Pulendran B. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011, 470:543-547.
27. Khan S., Bijker M.S., Weterings J.J., Tanke H.J., Adema G.J., van Hall T., Drijfhout J.W., Melief C.J.M., Overkleeft H.S., van der Marel G.A., Filippov D.V., van der Burg S.H., Ossendorp F. Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells. J. Biol. Chem. 2007, 282:21145-21159.
28. Khan S., Weterings J.J., Britten C.M., de Jong A.R., Graafland D., Melief C.J.M., van der Burg S.H., van der Marel G., Overkleeft H.S., Filippov D.V., Ossendorp F. Chirality of TLR-2 ligand Pam3CysSK4 in fully synthetic peptide conjugates critically influences the induction of specific CD8+ T-cells. Mol. Immunol. 2009, 46:1084-1091.
29. Kiura K., Hasebe A., Saeki A., Segawa T., Okada F., Shamsul H.M., Ohtani M., Into T., Inoue N., Wakita M., Shibata K.-I. In vivo anti- and pro-tumour activities of the TLR2 ligand FSL-1. Immunobiology 2011, 216:891-900.
30. Kiura K., Kataoka H., Yasuda M., Inoue N., Shibata K.-I. The diacylated lipopeptide FSL-1 induces TLR2-mediated Th2 responses. FEMS Immunol. Med. Microbiol. 2006, 48:44-55.
31. Lau Y.F., Deliyannis G., Zeng W., Mansell A., Jackson D.C., Brown L.E. Lipid-containing mimetics of natural triggers of innate immunity as CTL-inducing influenza vaccines. Int. Immunol. 2006, 18:1801-1813.
32. Lee C.H., Masso-Welch P., Hajishengallis G., Connell T.D. TLR2-dependent modulation of dendritic cells by LT-IIa-B5, a novel mucosal adjuvant derived from a type II heat-labile enterotoxin. J. Leukoc Biol. 2011, 90:911-921.
33. Leitão A., Malur A., Cartaxeiro C., Vasco G., Cruz B., Cornelis P., Martins C.L. Bacterial lipoprotein based expression vectors as tools for the characterisation of African swine fever virus (ASFV) antigens. Arch. Virol. 2000, 145:1639-1657.
34. Leitão A., Malur A., Cornelis P., Martins C.L. Identification of a 25-aminoacid sequence from the major African swine fever virus structural protein VP72 recognised by porcine cytotoxic T lymphocytes using a lipoprotein based expression system. J. Virol. Methods 1998, 75:113-119.
35. Leng C.-H., Chen H.-W., Chang L.-S., Liu H.-H., Liu H.-Y., Sher Y.-P., Chang Y.-W., Lien S.-P., Huang T.-Y., Chen M.-Y., Chou A.-H., Chong P., Liu S.-J. A recombinant lipoprotein containing an unsaturated fatty acid activates NF-kappaB through the TLR2 signaling pathway and induces a differential gene profile from a synthetic lipopeptide. Mol. Immunol. 2010, 47:2015-2021.
36. Link C., Gavioli R., Ebensen T., Canella A., Reinhard E., Guzmán C.A. The Toll-like receptor ligand MALP-2 stimulates dendritic cell maturation and modulates proteasome composition and activity. Eur. J. Immunol. 2004, 34:899-907.
37. Liu Z., Liu J.-Q., Talebian F., Wu L.-C., Li S., Bai X.-F. IL-27 enhances the survival of tumor antigen-specific CD8+ T cells and programs them into IL-10-producing, memory precursor-like effector cells. Eur. J. Immunol. 2013, 43:468-479.
38. Lombardi V., Van Overtvelt L., Horiot S., Moussu H., Chabre H., Louise A., Balazuc A.M., Mascarell L., Moingeon P. Toll-like receptor 2 agonist Pam3CSK4 enhances the induction of antigen-specific tolerance via the sublingual route. Clin. Exp. Allergy 2008, 38:1819-1829.
39. Manicassamy S., Ravindran R., Deng J., Oluoch H., Denning T.L., Kasturi S.P., Rosenthal K.M., Evavold B.D., Pulendran B. Toll-like receptor 2-dependent induction of vitamin A-metabolizing enzymes in dendritic cells promotes T regulatory responses and inhibits autoimmunity. Nat. Med. 2009, 15:401-409.
40. Martinon F., Gras-Masse H., Boutillon C., Chirat F., Deprez B., Guillet J.G., Gomard E., Tartar A., Levy J.P. Immunization of mice with lipopeptides bypasses the prerequisite for adjuvant. Immune response of BALB/c mice to human immunodeficiency virus envelope glycoprotein. J. Immunol. 1992, 149:3416-3422.
41. Mele T., Madrenas J. TLR2 signalling: at the crossroads of commensalism, invasive infections and toxic shock syndrome by Staphylococcus aureus. Int. J. Biochem. Cell Biol. 2010, 42:1066-1071.
42. Nardelli B., Haser P.B., Tam J.P. Oral administration of an antigenic synthetic lipopeptide (MAP-P3C) evokes salivary antibodies and systemic humoral and cellular responses. Vaccine 1994, 12:1335-1339.
43. Natividad K.D.T., Junankar S.R., Mohd Redzwan N., Nair R., Wirasinha R.C., King C., Brink R., Swarbrick A., Batten M. Interleukin-27 signaling promotes immunity against endogenously arising murine tumors. PLoS One 2013, 8.
44. Pulendran B., Kumar P., Cutler C.W., Mohamadzadeh M., Van Dyke T., Banchereau J. Lipopolysaccharides from distinct pathogens induce different classes of immune responses in vivo. J. Immunol. 2001, 167:5067-5076.
45. Pulendran B., Tang H., Manicassamy S. Programming dendritic cells to induce T(H)2 and tolerogenic responses. Nat. Immunol. 2010, 11:647-655.
46. Redecke V., Häcker H., Datta S.K., Fermin A., Pitha P.M., Broide D.H., Raz E. Cutting edge: activation of Toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma. J. Immunol. 2004, 172:2739-2743.
47. Revets H., Pynaert G., Grooten J., De Baetselier P. Lipoprotein I, a TLR2/4 ligand modulates Th2-driven allergic immune responses. J. Immunol. 2005, 174:1097-1103.
48. Sanderson S., Shastri N. LacZ inducible, antigen/MHC-specific T cell hybrids. Int. Immunol. 1994, 6:369-376.
49. Sieling P.A., Chung W., Duong B.T., Godowski P.J., Modlin R.L. Toll-like receptor 2 ligands as adjuvants for human Th1 responses. J. Immunol. 2003, 170:194-200.
50. Thoma-Uszynski S., Kiertscher S.M., Ochoa M.T., Bouis D.A., Norgard M.V., Miyake K., Godowski P.J., Roth M.D., Modlin R.L. Activation of toll-like receptor 2 on human dendritic cells triggers induction of IL-12, but not IL-10. J. Immunol. 2000, 165:3804-3810.
51. van Duin D., Medzhitov R., Shaw A.C. Triggering TLR signaling in vaccination. Trends Immunol. 2006, 27:49-55.
52. Vignali D.A., Kuchroo V. IL-12 family cytokines: immunological playmakers. Nat. Immunol. 2012, 13:722-728.
53. Wang S., Villablanca E.J., De Calisto J., Gomes D.C.O., Nguyen D.D., Mizoguchi E., Kagan J.C., Reinecker H.-C., Hacohen N., Nagler C., Xavier R.J., Rossi-Bergmann B., Chen Y.-B., Blomhoff R., Snapper S.B., Mora J.R. MyD88-dependent TLR1/2 signals educate dendritic cells with gut-specific imprinting properties. J. Immunol. 2011, 187:141-150.
54. Warshakoon H.J., Hood J.D., Kimbrell M.R., Malladi S., Wu W.Y., Shukla N.M., Agnihotri G., Sil D., David S.A. Potential adjuvantic properties of innate immune stimuli. Hum. Vaccin. 2009, 5:381-394.
55. Watanabe T., Kitani A., Murray P.J., Strober W. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat. Immunol. 2004, 5:800-808.
56. West M.A., Wallin R.P.A., Matthews S.P., Svensson H.G., Zaru R., Ljunggren H.-G., Prescott A.R., Watts C. Enhanced dendritic cell antigen capture via toll-like receptor-induced actin remodeling. Science (New York, NY) 2004, 305:1153-1157.
57. Yamazaki S., Okada K., Maruyama A., Matsumoto M., Yagita H., Seya T. TLR2-dependent induction of IL-10 and Foxp3+ CD25+ CD4+ regulatory T cells prevents effective anti-tumor immunity induced by Pam2 lipopeptides in vivo. PLoS One 2011, 6:e18833.
58. Zeng W., Ghosh S., Lau Y.F., Brown L.E., Jackson D.C. Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J. Immunol. 2002, 169:4905-4912.
59. Zhang X., Chentoufi A.A., Dasgupta G., Nesburn A.B., Wu M., Zhu X., Carpenter D., Wechsler S.L., You S., BenMohamed L. A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge. Mucosal Immunol. 2009, 2:129-143.
60. Zhang X., Issagholian A., Berg E.A., Fishman J.B., Nesburn A.B., BenMohamed L. Th-cytotoxic T-lymphocyte chimeric epitopes extended by Nepsilon-palmitoyl lysines induce herpes simplex virus type 1-specific effector CD8+ Tc1 responses and protect against ocular infection. J. Virol. 2005, 79:15289-15301.
61. Zhu X., Ramos T.V., Gras-Masse H., Kaplan B.E., BenMohamed L. Lipopeptide epitopes extended by an Nepsilon-palmitoyl-lysine moiety increase uptake and maturation of dendritic cells through a Toll-like receptor-2 pathway and trigger a Th1-dependent protective immunity. Eur. J. Immunol. 2004, 34:3102-3114.